This report describes the long-term follow-up data of three consecutive Dutch Childhood Oncology Group acute myeloid leukemia (AML) protocols. A total of 303 children were diagnosed with AML, of whom 209 were eligible for this report. The first study was the AML-82 protocol. Results were inferior (5-year probability of overall survival (pOS) 31%) to other available regimes. Study AML-87 was based on the BFM-87 protocol, with prophylactic cranial irradiation in high-risk patients only, and without maintenance therapy. This led to a higher cumulative incidence of relapse than that reported by the Berlin-Frankfurt-Mü nster (BFM), but survival was similar (5-year pOS 47%), suggesting successful retrieval at relapse. The subsequent study AML-92/94 consisted of a modified BFM-93 protocol, that is, without maintenance therapy and prophylactic cranial irradiation. However, all patients were to be transplanted (auto-or allogeneic), although compliance was poor. Antileukemic efficacy was offset by an increase in the cumulative incidence of nonrelapse mortality, especially in remission patients, and survival did not improve (5-year pOS 44%). Our results demonstrate that outcome in childhood AML is still unsatisfactory, and that further intensification of therapy carries the risk of enhanced toxicity. Our patients are currently included in the MRC AML studies, based on the results of their AML 10 trial.
Introduction
Before the 1980s, there was no nationwide acute myeloid leukemia (AML) study in the Netherlands. In the 1960s and 1970s, children with AML were treated with acute lymphoblastic leukemia (ALL) protocols or according to institutional guidelines. In a retrospective Dutch Childhood Oncology Group (DCOG) study published in 1975, it appeared that of the 57 children with AML diagnosed between 1965 and 1967, no patients survived after 4 years of follow-up. 1 Considering the improving results with subsequent national protocols for ALL, 2 it was anticipated that the same could be achieved in AML. The first national AML trial was therefore initiated in 1982 after a preceding pilot phase (AML-80). 3 We here describe the long-term treatment results of three subsequent DCOG (formerly known as the Dutch Childhood Leukemia Study Group) AML protocols, that is, AML-82, AML-87 and AML-92/94. These studies were nonrandomized singlearm studies due to the limited number of available patients. Details regarding treatment-related mortality occurring on these three protocols have recently been published in this journal. 4 Background and treatment strategy of the AML DCOG trials
Treatment protocols
From January 1983 to June 1998, three consecutive treatment protocols for children with AML were initiated in the Netherlands (Table 1) . Protocol AML-82 was based on the VAPA-10 protocol (developed in the Dana-Farber Cancer Institute, Boston, MA, USA), 5 whereas the two subsequent Dutch protocols (AML-87 and -92/94) were based on their respective Berlin-Frankfurt-Mü nster (BFM) counterparts. 6, 7 The protocols are depicted schematically (available as Supplementary Figure 1 on the Leukemia website), and details are given in Table 2 . Dose-reduction guidelines were applied for infants only.
AML-82
Induction treatment consisted of cytarabine pushes and doxorubicin. The time interval between the cytarabine pushes was based on a 'calibration curve', determined by the percentage of bone marrow blast cells in S-phase after the first cytarabine push, and varied from 11 to 30 h. Children with high initial white blood cell counts (WBCs, defined as X100 Â 10 9 /l), who did not achieve complete remission (CR) after the first induction course, were treated with a second similar induction block. Following peripheral blood regeneration, intensification therapy was started. Subsequently, patients with an available matched sibling donor (MSD) received an allogeneic stem cell transplant (allo-SCT). Patients without a donor were treated further with maintenance treatment according to the VAPA-10 protocol. This consisted of four blocks of chemotherapy that were given with 3-4 weeks intervals, and were repeated four times (16 blocks in total) . No prophylactic cranial irradiation was given, and there was no intrathecal chemotherapy. High-dose cytarabine was considered to be adequate for central nervous system (CNS) prophylaxis. 8 
AML-87:
The Dutch AML-87 protocol was largely similar to the BFM-87 study. 6 It was designed with the aim to improve prognosis in patients who were not transplanted by introducing two blocks of intensification chemotherapy following consolidation.
Only children with high-risk AML (according to the BFM criteria 6 ) and with an available MSD received allo-SCT, directly following consolidation. All patients received prophylactic intrathecal chemotherapy with cytarabine, for a total of five injections. However, different from the original BFM protocol, only children with a WBC 470 Â 10 9 /l at diagnosis were treated with prophylactic cranial irradiation (which was given according to age: below 1 year, no irradiation; 1-2 years, 12 Gy; 2-3 years, 15 Gy; 43 years, 18 Gy), and no maintenance therapy was given. The total duration of treatment was approximately 4-6 months.
AML-92/94: Protocol AML-94 was preceded by a pilot phase, which started in 1992 (AML-92 pilot). The pilot study was implemented without any changes in 1994, and we present here the data together as study AML-92/94 (Hählen et al. Med Pediatr Oncol 2001; 35: 251). This protocol was highly similar to the BFM-93 study, 7 and was designed with the aim to improve prognosis by replacing daunorubicin in induction by idarubicin, and to reduce the number of early relapses by introducing an early intensification course following induction (double induction). In addition, all children were to be transplanted following the second intensification course, either by allograft, in case an MSD was available, or by autografting. The intensification course following induction consisted of highdose cytarabine and mitoxantrone, the so-called HAM course. CNS prophylaxis consisted of five intrathecal injections with cytarabine. No maintenance therapy and no prophylactic cranial irradiation were given. Children with acute promyelocytic leukemia received all-trans-retinoic acid (ATRA 25 mg/m 2 / day) together with the induction treatment.
Patients and methods

Eligibility
All children with newly diagnosed AML in the Netherlands, aged 0-15 years (AML-82 and -87 studies) or 0-18 years (AML-92/94 study), were eligible. Patients who received corticosteroids or chemotherapy longer than 2 weeks before diagnosis were excluded. Children with AML and Down's syndrome (DS), myelosarcoma or AML following myelodysplastic syndrome (MDS) were eligible, but patients with AML as secondary malignancy were not. Patients were included only after informed consent had been obtained. All children were treated in one of the seven pediatric oncology centers in the Netherlands.
Diagnosis
AML was diagnosed by cytomorphological and cytochemical examination, according to the FAB classification as described by Bennett et al, 
Definitions and statistical analysis
CR was defined as less than 5% blasts in the bone marrow, with regeneration of normal hematopoiesis, plus absence of leukemic cells in the spinal fluid or anywhere else on day 42 after the start of induction therapy. Early death (ED) was defined as patients who died during the first 6 weeks after initiating therapy, and included patients who were registered at the DCOG office but died of complications before treatment was started (death before treatment). Patients surviving the first 6 weeks of therapy but who failed to achieve remission on day 42 were classified as nonresponders (NR). Relapse was defined as 45% blasts in the bone marrow, or X15/3 ml blasts in the liquor, or leukemic infiltration elsewhere. Overall survival (OS) was defined as the time between diagnosis and death of any cause. Event-free survival (EFS) was defined as the time between diagnosis and first event (relapse, death of any cause, failure to achieve remission or second malignancy) or date of last follow-up. Patients who were classified as NR were considered as failures at time zero. Probabilities of survival were estimated by the method of Kaplan and Meier and were compared using the log-rank test. Cumulative incidence functions of relapse and nonrelapse mortality were constructed by the method of Marubini and Valsecchi. To evaluate the role of transplant, a Cox model for relapse incidence was used with treatment as time-dependent covariate. Analysis was performed on the basis of intent-to-treat principle. Actuarial survival parameters were given for patients who were followed up for at least 5 or 10 years. All surviving patients were censored at the 1st of January 2004. The patients who were lost to follow-up were censored at the day of their last follow-up. A P-value of o0.05 was considered statistically significant.
Results
Patients characteristics
From January 1983 to June 1998, a total of 303 children were diagnosed with AML. A total of 23 patients were not eligible. Of Long-term outcome of AML in the Netherlands G Kardos et al Table 2 AML treatment protocols of the Dutch Childhood Oncology Study Group Cytostatic drugs: Ara-C, cytarabine; aza, azacytidine; cyclo, cyclophosphamide; dox, doxorubicin; dnr, daunorubicin; ida, idarubicin; methylpred, methylprednisolone; mitox, mitoxantrone; 6-mp, 6-mercaptopurine; mtx, methotrexate; Pred, prednisolone; 6-TG, 6-thioguanine; vcr, vincristine; VP16, etoposide. SCT, stem cell transplant; HLA, human leukocyte antigen; ith, administered intrathecally, usually by lumbar puncture; i.v., intravenous; PR, partial remission; WBC, white blood cell count.
Long-term outcome of AML in the Netherlands G Kardos et al the 280 patients who fulfilled the eligibility criteria, 229 children (82%) were included in the three consecutive DCOG AML protocols. The other patients were treated according to institutional protocols, and were excluded from all analyses in this report. When children with Down's syndrome acute myeloid leukemia (DS AML), preceding MDS, isolated myelosarcoma and age X15 years were excluded, 209 children with newly diagnosed AML remained, who form the basis for this report (Table 1) . Patients characteristics are shown in Table 3 . Comparison of initial patients characteristics revealed no statistically significant differences between the three studies, except for an increase in the number of boys vs girls in the subsequent trials (P ¼ 0.019). In study AML-82, no patients were diagnosed with FAB type M0 or M7, because these AML subtypes were defined at a later date. Cytogenetic analysis was not performed in study AML-82, but was performed with increasing frequency in the subsequent protocols. There were no significant differences in the percentages of cytogenetically favorable and unfavorable subgroups between studies AML-87 and -92/94.
Overall outcome of the three consecutive studies
The remission rate increased from 67% in study AML-82 to 82% in the studies AML-87 and -92/94, which was borderline statistically significant (P ¼ 0.08) (data are summarized in Table 4 ). The probability of 5-year EFS (pEFS) increased over time from 29% (s.e. 7%) in study AML-82 to 39 (s.e. 6%) for study AML-87 and 42% (s.e. 6%) for study AML-92/94 (Figure 1 ; P ¼ 0.10). The slightly higher pEFS rate in study ANLL-92/94 did not translate into an increase in the 5-year probability of OS (pOS), which was 31% (s.e. 7%) in AML-82, 47% (s.e. 6%) in AML-87 and 42% (s.e. 6%) in AML-92/94 (P ¼ 0.26; available as Supplementary Figure 2 on the Leukemia website). This was mainly due to an increase in the 5-year cumulative incidence of nonrelapse mortality from study AML-87 of 15% (s.e. 4%) to 32% (s.e. 5%) for AML-92/94 (P ¼ 0.03), despite a reduction in the 5-year cumulative incidence of relapse from 47% (s.e. 6%) for study AML-87 to 26% (s.e. 5%) for study AML-92/94 (P ¼ 0.02). Median follow-up for patients treated according to study AML-82 protocol was 14.2 years, for the AML-87 protocol Table 1 ). As almost no events occurred after 5 years, the 10-year survival estimates for studies AML-82 and -87 are almost identical to the 5-year data (summarized in Table 4 ).
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Results of study AML-82
A total of 48 patients were treated according to this protocol. CR was achieved in 32 children (67%). A total of 13 (27%) children died before CR was achieved (including death before treatment and ED) and another four children (8%) failed to achieve CR (NR). Only one patient in CR died due to treatment-related mortality. The 10-year pOS was 31% (s.e. 7%), with a pEFS of 29% (s.e. 7%) and a 10-year cumulative incidence of relapse of 43% (s.e. 7%). The 10-year cumulative incidence of nonrelapse mortality was 30% (s.e. 7%). No events occurred later than 5 years from the start of therapy. There were no significant differences in clinical outcome related to sex, age, FAB subtypes or WBC at diagnosis. A total of 20 children relapsed, with CNS involvement in three children (two combined and one isolated CNS relapse). Most relapses occurred either during or shortly after stopping maintenance therapy.
Results of study AML-87
Of the 83 children enrolled in this study, 68 (82%) attained CR. Seven children (8%) died before CR was achieved and another eight (10%) children failed to achieve CR (NR). Only one patient in CR died due to treatment-related mortality. The 10-year pOS was 47% (s.e. 6%), the 10-year pEFS was 39% (s.e. 6%) and the 10-year cumulative incidence of relapse was 47% (s.e. 6%). The 10-year cumulative incidence of nonrelapse mortality was 15% (s.e. 4%). There were no significant differences in clinical outcome related to sex, age, FAB subtypes or WBC at diagnosis. Of the 38 children who relapsed, five were diagnosed with isolated CNS relapse. None of these children had received prophylactic cranial irradiation in first remission. No combined CNS and bone marrow relapses occurred. 
Figure 1
The 5-year pEFS of the three consecutive DCOG AML studies. The 5-year pEFS increased over time, that is, the pEFS for study AML-82 was 29% (s.e. 7%), for AML-87, 39% (s.e. 6%) and for AML-92/94, 42% (s.e. 6%); P log rank ¼ 0.10. CCR, continuous complete remission; OS, overall survival; EFS, event-free survival; DFS, disease-free survival; SCT, stem cell transplantation; LFU, lost to follow-up.
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Results of study AML-92/94
A total of 78 patients received treatment according to this protocol, and 64 of them (82%) achieved CR. Eight children (10%) died before CR was achieved (including death before treatment and EDs) and another six children (8%) failed to achieve CR (NR). A high number of patients (n ¼ 10) died in CR due to treatment-related mortality. The 5-year pOS was 42% (s.e. 6%), the 5-year pEFS was 42% (s.e. 6%), but the 5-year cumulative incidence of relapse was relatively low (26%, s.e. 5%). However, the 5-year cumulative incidence of nonrelapse mortality increased to 32% (s.e. 5%). There were no significant differences in clinical outcome related to sex, age, FAB subtypes or WBC at diagnosis. Of the 20 children who relapsed, three had isolated CNS relapse. Again, no combined CNS and bone marrow relapses occurred.
Transplanted patients
In each of the protocols, some patients were transplanted and others were not. This was mainly due to individual decisions by doctors and patients based on the condition of the patient and, in the later studies, also on cytogenetic risk groups, despite the protocol recommendation in study 92/94 to either auto-or allograft all patients. In study AML-82, eight patients received an allotransplant. In study 87, a sibling SCT in first CR was performed in 20 children and another 14 patients were autografted. In study 92/94, a sibling SCT was performed in 21 patients, and 25 patients were treated with an autologous transplant. When the three protocols were taken together, there was no significant difference in the cumulative incidence of relapses (with treatment as time-dependent covariate) between patients treated with chemotherapy alone vs auto-or allotransplanted patients (P ¼ 0.342).
Toxicity
The 5-year cumulative incidence for nonrelapse mortality was 30% (s.e. 7%) for protocol AML-82, 15% (s.e. 4%) for protocol AML-87 and 32% (s.e. 5%) for protocol AML-92/94. However, the pattern of mortality changed, that is, in study AML-82 most deaths occurred before or in induction, whereas in study AML-92/94 mortality mainly occurred in CR, as described in more detail below. In total, 10 out of 209 children (5%) died before antileukemic treatment was initiated, due to intracranial and/or gastrointestinal bleeding, leucostasis or cardiac failure. The ED rate was as high as 22% in study AML-82, but decreased to 4 and 7% in the subsequent AML-87 and -92/94 studies. Most EDs were due to hemorrhage early in induction, whereas during the second part of induction, neutropenic fever was more frequent. 4 Whereas death in remission was infrequent (one out of 32 patients) in the AML-82 and in the AML-87 studies (one out of 68 patients), it was exceptionally high (10 out of 64 patients) in study AML-92/ 94. In the AML-92/94 study, five of the children treated with chemotherapy died, mainly due to infection in aplasia; the five other children died due to transplant-related complications.
Three patients developed secondary malignancies: basal cell carcinoma (n ¼ 1), secondary MDS (n ¼ 1) and secondary AML (n ¼ 1). No other serious late toxicities were observed so far; however, no systematic follow-up data about late effects such as cardiac toxicity and fertility are available.
Subgroup analysis
For subgroups with a sample size larger than 10 patients, subgroup analysis was performed (results are given in Table 5 ). In study AML-82, boys fared better than girls, although this was not statistically significant (P ¼ 0.21). In studies AML-87 and -92/ 94, there was no difference in outcome related to sex. There was 
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For instance, in study AML-87, children under 2 years of age had a better outcome than older children (P ¼ 0.45), whereas in study AML-92/94, older children did significantly better than younger children (P ¼ 0.02). Considering WBC, all three studies showed a decline in outcome with higher WBCs (X100 Â 10 9 /l) at diagnosis. Within each study, these differences were not significant, but when all three studies were taken together, children with high WBCs at diagnosis did significantly worse than children with lower WBCs (5-year pEFS 27% (s.e. 7%) vs 40% (s.e. 0%); P ¼ 0.05). There was no clear relationship between outcome and FAB classification. Considering cytogenetics, only in study AML-92/94 the majority of patients were karyotyped. There was no clear outcome benefit for patients with favorable cytogenetics (t(8;21), inv (16) and t(15;17) ), but numbers were small.
Down's syndrome AML
A total of 14 children with DS were diagnosed with AML. Half of them were younger than 2 years of age at diagnosis. The FAB type distribution showed seven FAB M0, two FAB M6 and five FAB M7 cases. Clinical outcome improved over time (5-year pEFS 50% (s.e. 20%) for study AML-87 vs 71% (s.e. 17%) for study AML-92/94), but numbers were too small for statistical analysis. Overall, children with DS AML did better than children without DS and AML (5-year pEFS 57% (s.e. 13%) vs 38% (s.e. 3%)), but the difference did not reach statistical significance (P ¼ 0.27).
Discussion
The AML-82 study was the first national protocol for children with AML in the Netherlands, and was based on the VAPA-10 protocol. 5 The main aim of this protocol was to study whether an individually scheduled Ara-C induction regimen (based on recruitment of cells in S-phase) could increase the remission rate and improve survival, although it was not a randomized study. 8 However, the 65% remission rate was lower when compared with the concurrent BFM studies (79 and 76% for AML-BFM-78 and -83, respectively), 12 and slightly inferior to the 70% CR rate as reported for the VAPA protocol. 13 Apart from induction failures, a large number of patients included in the AML-82 study relapsed, either during or early after the maintenance treatment phase, and results were inferior to the original VAPA-10 regimen. 13 One reason for the high number of relapses could be the long time interval between induction and intensification, which might have allowed leukemic regrowth.
Because of the inferior results of the AML-82 protocol, the next study (AML-87) was based on the successful BFM regimen. At the time of design of the Dutch AML-87 study, patients treated with the AML-BFM-83 protocol achieved EFS rates of approximately 55%, which was superior to all other studies, although follow-up was still short. 6 The backbone of the AML-BFM-83 protocol is an intensive induction course followed by a 6-week consolidation block, as well as the use of maintenance therapy and prophylactic cranial irradiation. 6 In the Dutch AML-87 study, we basically applied the newly designed AML-BFM-87 protocol with several modifications. First of all, we restricted the use of prophylactic cranial irradiation to patients with high WBCs at diagnosis (470 Â 10 9 /l), based on preliminary data from the AML BFM group that CNS relapses occurred more frequently in these children. In addition, we wanted to avoid the potential late morbidity caused by CNS irradiation, as was reported for ALL, 14 and later confirmed by others for AML as well. 15, 16 In addition, we omitted maintenance therapy, because of lack of established benefit for maintenance therapy in AML, and the risk that prolonged therapy might increase the death rate in CR. 17 Moreover, children with 'good-risk AML' (according to the BFM criteria) were not eligible for transplant. Despite these modifications, the remission and OS rates obtained with the Dutch AML-87 protocol were similar to those obtained by the BFM group. 12 However, the cumulative incidence of relapses in the BFM study was much lower than in our study, that is, 30.6 vs 47%. These data suggest that the antileukemic efficacy of our protocol was less than the BFM protocol, but that relapsed patients could be salvaged at relapse. 12 Of interest, two randomized studies conducted by the Children's Cancer Group and the French LAME group showed that patients receiving maintenance therapy experience lower survival rates due to poor retrieval at relapse. 18, 19 Most patients did not receive prophylactic cranial irradiation, and five out of 38 relapses involved the CNS. This addresses the need for prophylactic cranial irradiation in pediatric AML -but since we have not performed a randomized comparison, this question cannot be answered by our data. In general, CNS relapse is rare in pediatric AML (3-5%), and most groups do not use prophylactic cranial irradiation. 20 The BFM group randomized prophylactic cranial irradiation in patients with a WBC below 70 Â 10 9 /l in their AML-BFM-87 study, looking at reduction in relapse rate. They reported a reduction especially in bone marrow relapses, but also in CNS relapses in the irradiated group. 7 However, the results were only statistically significant when randomized and nonrandomized patients were taken together, and hence the question remains formally unanswered to date. 12 In addition, as cranial irradiation mainly improved systemic disease control, it leaves us with the question of whether this cannot better be obtained by more intensive or different chemotherapy.
Although the overall results from study AML-87 showed improvement compared to study AML-82, they were far from satisfactory. Hence, the major goal of the next protocol was to improve survival by further intensification of treatment. We again followed the BFM strategy for the design of the AML-92/94 protocol, which was similar to the concurrent AML-BFM 93 study. 21, 22 However, we again omitted maintenance therapy and prophylactic cranial irradiation (this time for all patients). In induction, idarubicin replaced daunorubicin, based on higher efficacy of idarubicin in three randomized studies in adults [23] [24] [25] as well as a pilot study in children. 26 In addition, the idarubicin metabolite idarubicinol had been detected in CNS fluid in children with leukemia, 27 and preliminary data suggested that idarubicin was perhaps less cardiotoxic than other anthracyclines. 28 With the introduction of an early intensification or 'double induction' course (HAM), which had proven to be very effective in adults with refractory AML, it was aimed to increase CR rate and reduce the relapse rate. 29 Autologous transplants were applied successfully in other trials, and led to improved survival, which was the basis for the recommendation in the protocol to either auto-or allograft all patients. 30, 31 Unfortunately, the slightly higher pEFS for study AML-92/94 did not result in improved OS. Moreover, clinical outcome was worse when compared with the concurrent AML-BFM 93 study. 21, 22, 32 This was mainly caused by the high nonrelapse mortality that occurred in study AML-92/94, despite potential better antileukemic efficacy demonstrated by a lower cumulative incidence of relapse. 4 Only three out of 20 relapses involved the CNS, again without prophylactic cranial irradiation. In the meantime, the POG reported no advantage for autografting in pediatric AML, resulting in less compliance with the study design of AML-92/94 to transplant all patients. 33 Our studies were not designed to address the issue of SCT vs intensive chemotherapy as optimal consolidation, and compliance with the protocols regarding transplantation was often violated, resulting in strong selection bias. When we analyzed the results with transplant as a time-dependent variable, we could not identify a lower cumulative incidence of relapse for transplanted patients. The role of transplant in pediatric AML remains subject to debate, and may depend heavily on the results obtained with combination chemotherapy. 34, 35 Both the BFM and the MRC groups tend to reserve transplant in first CR for high-risk patients only. In low-risk patients, the potential better disease control may be outweighed by increased procedure-related mortality.
Following protocol AML-92/94, the DCOG AML committee decided, based on the very encouraging results of the MRC AML 10 trial, to join the MRC AML 12 study. 36 This also gave us the possibility to enter our patients on a larger study, which was sufficiently powered to answer randomized questions, rather than running our own trials with small numbers of patients.
We conclude that our results obtained with the AML-82 protocol were inferior to the results obtained with other protocols in that time frame. The results achieved with the AML-87 protocol showed improved survival, similar to the AML-BFM-87 study, but without cranial irradiation in most patients and without maintenance therapy. Unfortunately, increased treatment-related mortality counterbalanced the anti-leukemic efficacy using the intensive AML-92/94 protocol, and survival rates did not improve.
Further improvements in AML should focus on better stratification of patients in defined risk groups, [37] [38] [39] which reduces the number of children receiving overly toxic treatment. The differential treatment strategies for children with acute promyelocytic leukemia 40 and AML in DS 41 are clear examples of this approach. In addition, the role of new targeted drugs, such as gemtuzumab ozogamicin and FLT3 inhibitors, needs to be established by future clinical studies. 42, 43 
